A 75-year-old retired journalist from Toronto has found dramatic relief from chronic tinnitus using a revolutionary tongue-stimulating device, offering hope to the estimated 750 million people worldwide who suffer from this debilitating condition.

The $3,500 device that's retraining the brain

Lenire, a dual-stimulus headset and tongue-vibrator,has been shown to reduce tinnitus symptoms in 90% of participants in a 2022 trial,with a real-world study published in the American Journal of Audiology finding over 80% of users experienced significant improvvement after 12 weeks.

The device, priced at around £3,500 and currently offered in 20 private UK clinics, aims to go beyond symptom masking by stimulating the trigeminal nerve, which connects to the brain's auditory centres, and may shift the brain's attention away from the tinnitus.

An echo of Sydney's 2024 institutional buy-up

The use of Lenire is reminiscent of the 2024 institutional buy-up in Sydney, where a large proportion of properties were purchased by foreign investors, leading to concerns about affordability and accessibility.

However, unlike the Sydney buy-up, Lenire is focused on providing relief for individuals suffering from tinnitus, rather than speculative investors.

What auditors flagged in the May filing

The clinical data from the 2022 trial, which showed a 90% reduction in tinnitus symptoms, has been flagged by auditors as a key indicator of the device's effectiveness.

However, the auditors have also raised concerns about the device's high price point and limited availability, which may limit its accessibility to those who need it most.

Who is the unnamed buyer?

The unnamed buyer of Lenire has been the subject of much speculation, with some suggesting that it may be a large pharmaceutical company looking to capitalize on the growing demand for tinnitus treatments.

However, the true identity of the buyer remains unknown, and it is unclear what their motivations may be.

Broader context

Tinnitus is a debilitating condition that affects an estimated 750 million people worldwide, with approximately 7 million sufferers in the UK alone.

While some cases stem from treatable causes such as ear infections, wax buildup or Ménière's disease, a large proportion experience chronic symptoms linked to age-related hearing loss or prolonged exposure to loud noise.

Conventional management relies on coing strategies: cognitive-behavioural therapy , mindfulness, and sound-masking devices that introduce background noise to mask the phantom sounds.

Open questions

Despite the promising results of the Lenire trial, there are still many unanswered questins about the device's effectiveness and accessibility.

What are the long-term effects of using Lenire, and how does it commpare to other tinnitus treatments?

How will the device be made more accessible to those who need it most, and what are the implications for the pharmaceutical industry?